Ligand Pharm (LGND)

Jan 13, 2025, 6:10 PM EST - 4 days ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

Dec 10, 2024, 9:00 AM EST - 5 weeks ago

Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance

Nov 24, 2024, 6:50 AM EST - 7 weeks ago

Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies

Nov 14, 2024, 8:00 AM EST - 2 months ago

Ligand to Present at Stifel 2024 Healthcare Conference

Nov 8, 2024, 8:07 AM EST - 2 months ago

Ligand Pharmaceuticals Incorporated (LGND) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 7:00 AM EST - 2 months ago

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

Nov 1, 2024, 8:01 AM EDT - 2 months ago

Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston

Oct 23, 2024, 4:01 PM EDT - 3 months ago

Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024

Sep 6, 2024, 9:20 AM EDT - 4 months ago

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

TVTX

Aug 30, 2024, 4:04 AM EDT - 5 months ago

CD40 Ligand Market - Global Monoclonal Antibody, Polyclonal Antibody, Autoimmune Disease Treatment, Immunotherapy, Vaccine Development Forecast 2024-2030

Aug 20, 2024, 9:00 AM EDT - 5 months ago

Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 6, 2024, 10:58 PM EDT - 5 months ago

Ligand Pharmaceuticals Incorporated (LGND) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:01 PM EDT - 5 months ago

Ligand Reports Second Quarter 2024 Financial Results

Jul 29, 2024, 2:43 PM EDT - 6 months ago

Ligand Pharmaceuticals: Solid Performer Performing Solidly

Jul 24, 2024, 6:30 AM EDT - 6 months ago

Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement

Jul 23, 2024, 4:01 PM EDT - 6 months ago

Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024

Jul 8, 2024, 7:00 AM EDT - 6 months ago

Ligand to Acquire APEIRON Biologics AG for $100 Million

Jun 27, 2024, 8:00 AM EDT - 7 months ago

Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years

Jun 18, 2024, 8:00 AM EDT - 7 months ago

Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults

May 23, 2024, 4:59 PM EDT - 8 months ago

Ligand to Participate in Upcoming Investor Conferences

May 7, 2024, 11:03 PM EDT - 9 months ago

Ligand Pharmaceuticals Incorporated (LGND) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:00 PM EDT - 9 months ago

Ligand Reports First Quarter 2024 Financial Results

May 7, 2024, 7:30 AM EDT - 9 months ago

Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement

AGEN

Apr 29, 2024, 10:01 PM EDT - 9 months ago

Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio

Apr 23, 2024, 8:31 AM EDT - 9 months ago

Ligand to Report First Quarter 2024 Financial Results on May 7, 2024

Apr 8, 2024, 8:15 AM EDT - 10 months ago

Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference

Apr 3, 2024, 9:00 AM EDT - 10 months ago

Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™

Mar 5, 2024, 4:01 PM EST - 11 months ago

Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference

Mar 4, 2024, 8:00 AM EST - 11 months ago

Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 27, 2024, 11:32 AM EST - 11 months ago

Ligand Pharmaceuticals Inc. (LGND) Q4 2023 Earnings Call Transcript

Feb 27, 2024, 7:00 AM EST - 11 months ago

Ligand Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 22, 2024, 4:01 PM EST - 11 months ago

Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®

Feb 16, 2024, 8:00 AM EST - 1 year ago

Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires

Feb 13, 2024, 4:01 PM EST - 1 year ago

Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

Feb 12, 2024, 5:00 AM EST - 1 year ago

Iambic Therapeutics Announces New Research Published in Nature Machine Intelligence Demonstrating the Capabilities of Its Generative AI NeuralPLexer Technology to Predict Protein-Ligand Complex Structures

Jan 5, 2024, 5:21 PM EST - 1 year ago

Ligand Pharma's at-home skin treatment gets FDA approval

Jan 5, 2024, 4:30 PM EST - 1 year ago

U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum

Dec 26, 2023, 12:18 PM EST - 1 year ago

20 favorite small-cap stocks for 2024 among Wall Street analysts

ARLO CPRX DGII DVAX GPRE HLX IRWD

Dec 12, 2023, 12:01 PM EST - 1 year ago

Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance

Dec 6, 2023, 4:02 PM EST - 1 year ago

Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City

Nov 15, 2023, 1:22 PM EST - 1 year ago

Ligand Pharmaceuticals: A Complicated Tale

Nov 8, 2023, 10:22 PM EST - 1 year ago

Ligand Pharmaceuticals Inc. (LGND) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 4:01 PM EST - 1 year ago

Ligand Reports Third Quarter 2023 Financial Results

Nov 1, 2023, 8:00 AM EDT - 1 year ago

Ligand Acquires Royalty on Sanofi's TZIELD® for $20 Million

SNY

Oct 25, 2023, 4:01 PM EDT - 1 year ago

Ligand To Report Third Quarter 2023 Financial Results On November 8

Sep 27, 2023, 9:00 AM EDT - 1 year ago

Ligand Acquires Assets of Novan, Inc. for $12.2 Million

Sep 26, 2023, 5:05 PM EDT - 1 year ago

Ligand Appoints Martine Zimmermann to its Board of Directors

Sep 22, 2023, 9:00 AM EDT - 1 year ago

Ligand's Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

JAZZ

Sep 21, 2023, 9:20 AM EDT - 1 year ago

Ligand's Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control

Sep 18, 2023, 5:17 PM EDT - 1 year ago

Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio